ARD: 对IL-1和IL-6抑制剂的严重迟发性超敏反应与常见的HLA-DRB1*15等位基因有关

2021-11-21 MedSci原创 MedSci原创

该研究分析了人类白细胞抗原(HLA)等位基因与IL-1/IL-6抑制剂相关迟发型超敏反应的关联。

      目的:嗜酸性粒细胞增多和全身症状的药物反应(DRESS)是一种严重的迟发性超敏反应(DHR)。斯蒂尔病(Still)是以发热、皮疹、关节炎/痛、淋巴结肿大、白细胞升高等为主要表现的罕见自身免疫性疾病。研究者在一小群患有非典型肺病的Still病患者中观察到白细胞介素1 (IL-1) IL-6抑制剂的DRESS。与耐药的Still疾病对照组相比,研究者试图表征有DRESSStill病患者的特征。研究者分析了人类白细胞抗原(HLA)等位基因与IL-1/IL-6抑制剂相关DHR的关联,包括一个小型川崎病(KD)队列。

     方法:在病例/对照研究中,研究者收集了具有抑制剂相关DRESS (n=66)和药物耐受Still 对照(n=65)特征的多中心系列Still病患者。回顾性分析了Still病的所有受试者的临床数据,并为HLA输入了94/131。欧洲Still's-DRESS病例与国际儿童关节炎遗传学联盟儿科Still病例(n = 550)的血统匹配,并比较HLA等位基因频率。还使用Still's-DRESS病例(n=64)与耐药Still对照(n=30)分析了HLA关联。KD受试者(n=19)也进行了类似的分析。

      结果Still’s-DRESS特征包括嗜酸性粒细胞增多(89%)AST-ALT升高(75%)和非消失性皮疹(95%88%涉及面部)。治疗期间与耐药Still(3%)相比,巨噬细胞活化综合征在StillDRESS中很常见(64%p=1.2×10-14)。研究者发现Still's-DRESS病例与INCHARGE Still对照相比(p=7.5×10-13),和自我鉴定、血统匹配Still对照相比(p=6.3×10-10),HLA-DRB1*15单倍型显著富集。在KD队列中,DRB1*15:01仅存在于疑似阿那白滞素(IL-1受体拮抗剂)反应的患者中。

     小结DRESS型反应发生在接受IL-1/IL-6抑制剂治疗的患者中,并且与常见的 HLA-DRB1*15单倍型密切相关。考虑处方HLA分型并警惕对这些药物的严重反应是有必要的。

 

出处:

Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Annals of the Rheumatic Diseases Published Online First: 17 November 2021. doi: 10.1136/annrheumdis-2021-220578

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2022-04-19 w984445tii
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2022-09-20 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 kzlchina
  6. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 marongnuan
  8. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 jjjiang0202
  9. [GetPortalCommentsPageByObjectIdResponse(id=2063782, encodeId=ba992063e825c, content=<a href='/topic/show?id=d8fc624113' target=_blank style='color:#2F92EE;'>#DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6241, encryptionId=d8fc624113, topicName=DRB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Apr 19 05:24:57 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034433, encodeId=ce2e2034433dd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Mon Jul 11 17:24:57 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984350, encodeId=2b5f1984350da, content=<a href='/topic/show?id=fef19285519' target=_blank style='color:#2F92EE;'>#超敏反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92855, encryptionId=fef19285519, topicName=超敏反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Fri May 06 11:24:57 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852815, encodeId=1fe418528153b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 20 19:24:57 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273814, encodeId=34ff12e381422, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484164, encodeId=8afa148416437, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502076, encodeId=6ad315020e613, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508314, encodeId=04df15083144f, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631240, encodeId=26b71631240ac, content=<a href='/topic/show?id=c9fc8954af' target=_blank style='color:#2F92EE;'>#HLA-DRB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8954, encryptionId=c9fc8954af, topicName=HLA-DRB1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dca21693714, createdName=lqrandywkz, createdTime=Tue Nov 23 03:24:57 CST 2021, time=2021-11-23, status=1, ipAttribution=)]

相关资讯

Lancet:Ziltivekimab可有效降低高动脉粥样硬化风险个体的炎症标志物

采用Ziltivekimab抑制IL-6明显减少了与动脉粥样硬化相关的炎症和血栓形成的生物标志物

JAMA:世卫组织研究证实IL-6抑制剂可降低新冠肺炎住院患者死亡风险

新冠肺炎住院患者使用IL-6抑制剂治疗可降低28天死亡风险。

Cardiovasc Diabetol:心脏脂肪体积和IL-6水平可预测糖尿病患者因新冠肺炎入院后的短期病情恶化和死亡风险

对因新冠肺炎入院的糖尿病患者进行心脏脂肪组织指数和IL-6测定,可以帮助医生更好地识别具有高短期内病情迅速恶化和早期死亡风险的患者

Lancet Rheumatology: 抑制IL-1和IL-6影响COVID-19患者抗SARS-CoV-2抗体的中和活性

评估危及生命的COVID-19经IL-6抑制剂治疗后康复患者的抗SARS-CoV-2抗体的滴度及其中和能力随着时间的变化.

ATVB:IL-6是传统危险因素与心肌梗死之间关联的介导因素

血浆IL-6和IL-6二元复合物浓度与未来心肌梗死显著相关。该研究的数据表明血浆IL-6和IL-6二元复合物的浓度升高均可以部分解释这一关联,其可能与吸烟者和高血压参与者MI发生风险增加有关。

Translational Psychiatry:血液IL-6、GDNF和BDNF可能是与情绪障碍、物质滥用障碍和自杀相关的外周生物标志物

血液IL-6、GDNF和BDNF可能是与情绪障碍、物质障碍和自杀相关的脑生物学信息丰富的外周生物标志物。